



Pressrelease October 2, 2009

GENOVIS: THE NEW SHARE ISSUE WAS OVERSUBSCRIBED BY 102%

On closing day, September 30, the new share issuing with preferential rights to existing shareholders in Genovis was oversubscribed by 102 %.

14.2 million shares was subscribed for in the new share issue that closed on September 30. In the new share issuing of 7,033,233 shares, 61 % was subscribed with preferential rights. Allotment of shares subscribed without subscription rights shall first hand go to those who subscribed with preferential rights proportional to their subscription for shares with preferential rights, and at second hand to those who subscribed without preferential rights proportional to their subscription.

The issuing ensures Genovis approximately 7 MSEK before issue expenses. The number of shares increased from 14,066,466 to 21,099,699 and the share capital increased from 5,626,586.40 to 8,439,879.60.

Contract note and notification of allotment of shares subscribed without subscription rights is estimated to be sent out Tuesday October 6, 2009.

As of October 1 Thenberg & Kinde Fondkommission is our certified advisor

For more information, contact:
Sarah Fredriksson, CEO, Genovis AB
+46-46-10 12 30
sarah.fredriksson@genovis.com

Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company's patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on Nasdaq OMX First North. Thenberg & Kinde Fondkommission is our certified advisor and Mangold Fondkommission is our liquidity guarantor.